

DOCKET NO.: CP245
Application No.: 10/660,058
Office Action Dated: April 4, 2007

PATENT

This listing of claims will replace all prior versions of claims in the application.

What is claimed is:

1. (cancelled)
2. (previously presented) A pharmaceutical unit dose consisting essentially of about 250 to about 350 mg of modafinil.
3. (currently amended) The unit dose of claim + 2 consisting essentially of about 275 to about 325 mg of modafinil.
4. (cancelled)
5. (currently amended) The unit dose of claim + 2 consisting essentially of 275 to 325 mg of modafinil.
6. (cancelled)
7. (currently amended) The unit dose of claim + 2 consisting essentially of 255 mg of modafinil.
8. (currently amended) The unit dose of claim + 2 consisting essentially of 300 mg of modafinil.
9. (currently amended) The unit dose of claim + 2 consisting essentially of 340 mg of modafinil.
10. (cancelled)

DOCKET NO.: CP245
Application No.: 10/660,058
Office Action Dated: April 4, 2007

PATENT

11. (withdrawn) A method of treating ADHD in a human subject comprising the step of administering a single dose of about 250 to about 450 mg of modafinil within a 24 hour period to the human subject.

12. (withdrawn) A method of treating ADHD in a human subject comprising the step of administering a single dose of about 250 to about 350 mg of modafinil within a 24 hour period to the human subject.

13. (withdrawn) The method of claim 11, wherein the subject is a pediatric subject.

14. (withdrawn) The method of claim 11, wherein about 425 mg of modafinil is administered to the subject.

15. (withdrawn) The method of claim 11, wherein about 340 mg of modafinil is administered to the subject.

16. (withdrawn) The method of claim 11, wherein about 300 mg of modafinil is administered to the subject.

17. (withdrawn) The method of claim 11, wherein about 255 mg of modafinil is administered to the subject.

18. (currently amended) A pharmaceutical unit dose consisting essentially of 300 mg of modafinil that, following oral administration to a human, results in a blood profile of modafinil substantially as shown in Fig. 3, wherein the blood plasma level of modafinil begins to decrease after about 2 hours post administration, providing improved attention and ADHD symptoms resulting from blood concentrations of modafinil which are about 20-30% less than predicted.

DOCKET NO.: CP245
Application No.: 10/660,058
Office Action Dated: April 4, 2007

PATENT

19. (withdrawn) A method of treating ADHD in a human subject with modafinil, comprising the step of administering to the subject a single dose of modafinil in a 24 hour period that is sufficient to induce a blood profile of modafinil substantially as shown in Fig. 3.

20. (currently amended) The unit dose of claim ~~1~~ 2, wherein the amount of modafinil in the unit dose is selected from the group consisting essentially of 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345 and 350 mgs of modafinil.

21. (currently amended) ~~The unit dose of claim 1~~ A pharmaceutical unit dose, wherein the amount of modafinil in the unit dose is selected from the group consisting essentially of 355, 360, 365, 370, 375, 380, 385, 390, 395, ~~400~~, 405, 410, 415, 420, 425, 430, 435, 440, 445, and 450 mg of modafinil.

22. (currently amended) The unit dose of claim ~~1~~ 2, wherein the amount of modafinil in the pharmaceutical unit dose is selected from the group consisting of 255, 300, and 340 ~~and 425~~ mgs of modafinil.

23. (currently amended) The unit dose of claim ~~1~~ 2, wherein about 70 to 75% of the total tablet weight is modafinil.

24. (currently amended) The unit dose of claim ~~1~~ 2, wherein about 80% of the total tablet weight is modafinil.

25. (cancelled)

DOCKET NO.: CP245
Application No.: 10/660,058
Office Action Dated: April 4, 2007

PATENT

26. (previously presented) A pharmaceutical composition comprising about 250 to about 350 mg of modafinil.

27. (currently amended) The composition of claim ~~25~~ 26 comprising about 275 to about 325 mg of modafinil.

28. (cancelled)

29. (currently amended) The composition of claim ~~25~~ 26 comprising 275 to 325 mg of modafinil.

30. (cancelled)

31. (currently amended) The composition of claim ~~25~~ 26 comprising 255 mg of modafinil.

32. (currently amended) The composition of claim ~~25~~ 26 comprising 300 mg of modafinil.

33. (currently amended) The composition of claim ~~25~~ 26 comprising 340 mg of modafinil.

34. (cancelled)

35. (currently amended) A pharmaceutical composition comprising about 250 to about ~~450~~ 350 mg of modafinil that is free of magnesium silicate or talc.

DOCKET NO.: CP245
Application No.: 10/660,058
Office Action Dated: April 4, 2007

PATENT

36. (currently amended) The composition of claim 35 comprising one or more diluents, each independently chosen from a starch, a lactose monohydrate or a microcrystalline cellulose; one or more disintegrants, each independently chosen from a pregelatinized starch or a cross-linked sodium carboxymethyl cellulose; ~~a binder~~, and a lubricant.

37. (currently amended) The composition of claim 36, wherein ~~the binder is a polyvinyl pyrrolidone, and~~ the lubricant is magnesium stearate.

38. (previously presented) The composition of claim 35, wherein the composition is a tablet.

39. (previously presented) The composition of claim 35, wherein about 90% of the tablet weight is modafinil.

40. (previously presented) The composition of claim 35, wherein about 80% of the tablet weight is modafinil.

41. (currently amended) The unit dose of claim ~~1~~ 2, wherein the modafinil is R-(-)-2-[(diphenylmethyl)sulfinyl] acetamide.

42. (currently amended) The composition of claim ~~25~~ 26, wherein the modafinil is R-(-)-2-[(diphenylmethyl)sulfinyl] acetamide.

43. (cancelled)

44. (cancelled)

45. (new) A pharmaceutical unit dose consisting essentially of 425 mg of modafinil.

DOCKET NO.: CP245

PATENT

Application No.: 10/660,058

Office Action Dated: April 4, 2007

46. (new) A pharmaceutical composition comprising 425 mg of modafinil.